Role of high-risk human papillomaviruses in breast carcinogenesis

Cancer-Causing Viruses and their Inhibitors

Volumn , Issue , 2014, Pages 243-260

  Al Moustafa, Ala Eddin ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b Syrian Society Against Cancer   (Syrian Arab Republic)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84978608207     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16780     Document Type: Chapter

References (99)

1. Aguayo F, Khan N, Koriyama C, et al. (2011). Human papillomavirus and Epstein-Barr virus infections in breast cancer from Chile. Infect Agent Cancer 6: 7.
2. Akil N, Yasmeen A, Kassab A, et al. (2008). High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: At issue micro array study. Br J Cancer 99: 404-7.
3. Al Moustafa AE, Foulkes WD, Benlimame N, et al. (2004a). E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 23: 350-8.
4. Al Moustafa AE, Foulkes WD, Wong A, et al. (2004b). Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene 23: 5252-6.
5. Al Moustafa AE, Yasmeen A, Ghabreau L, Akil N. (2012). Does the Syrian population have to wait for the new generation of human papillomaviruses vaccine? Hum Vaccin Immunother 8: 1867-8.
6. Antinore MJ, Birrer MJ, Patel D, et al. (1996). The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO 15: 1950-60.
7. Antonsson A, Spurr TP, Chen AC, et al. (2011). High prevalence of human papillomaviruses in fresh frozen breast cancer samples. J Med Virol 83: 2157-63.
8. Begum S, Gillison ML, Ansari-Lari MA, et al. (2003). Detection of human papillomavirus in cervical lymph nodes: A highly effective strategy for localizing site of tumor origin. Clin Cancer Res 9: 6469-75.
9. Bernard HU. (2005). The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 32 Suppl 1: S1-6.
10. Bratthauer GL, Tavassoli FA, O’Leary TJ. (1992). Etiology of breast carcinoma: No apparent role for papillomavirus types 6/11/16/18. Pathol Res Pract 188: 384-6.
11. Brown DR, Kjaer SK, Sigurdsson K, et al. (2009). The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-35.
12. Castellsagué X, Díaz M, de Sanjosé S, et al., International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. (2006). Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst 98: 303-15.
13. Choi YL, Cho EY, Kim JH, et al. (2007). Detection of human papillomavirus DNA by DNA chip in breast carcinomas of Korean women. Tumour Biol 28: 327-32.
14. Coluccia AM, Benati D, Dekhil H, et al. (2006). SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res 66: 2279-86.
15. Daling JR, Madeleine MM, Johnson LG, et al. (2004). Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101: 270-80.
16. Damin AP, Karam R, Zettler CG, et al. (2004). Evidence for an association of human papillomavirus and breast carcinomas. Breast Cancer Res Treat 84: 131-7.
17. de Cremoux P, Thioux M, Lebigot I, et al. (2008). No evidence of human papillomavirus DNA sequences in invasive breast carcinoma. Breast Cancer Res Treat 109: 55-8.
18. de León DC, Montiel DP, Nemcova J, et al. (2009). Human papillomavirus (HPV) in breast tumors: Prevalence in a group of Mexican patients. BMC Cancer 9: 26.
19. de Villiers EM, Fauquet C, Broker TR, et al. (2004). Classification of papillomaviruses. Virology 324: 17-27.
20. de Villiers EM, Sandstrom RE, zur Hausen H, Buck CE. (2005). Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast. Breast Cancer Res 7: R1-11.
21. Desprez PY, Lin CQ, Thomasset N, Sympson CJ, et al. (1998). A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1. Mol Cell Biol 18: 4577-88.
22. Di Lonardo A, Venuti A, Marcante ML. (1992). Human papillomavirus in breast cancer. Breast Cancer Res Treat 21: 95-100.
23. Doorbar J. (2005). The papillomavirus lifecycle. J Clin Virol 32: S7-15.
24. Doorbar J. (2013). Latent papillomavirus infections and their regulation. Curr Opin Virol 3: 416-21.
25. Feller L, Wood NH, Khammissa RA, Lemmer J. (2010). Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part1: Human papillomavirus-mediated carcinogenesis. Head Face Med 6: 14.
26. Fong S, Itahana Y, Sumida T, et al. (2003). Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 100: 13543-8.
27. Funk JO, Waga S, Harry JB, et al. (1997). Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11: 2090-100.
28. Genther Williams SM, Disbrow GL, Schlegel R, et al. (2005). Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res 65: 6534-42.
29. Ghittoni R, Accardi R, Hasan U, et al. (2010). The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 40: 1-13.
30. Glenn WK, Heng B, Delprado W, et al. (2012). Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS One 7: e48788.
31. Gopalkrishna V, Singh UR, Sodhani P, et al. (1996). Absence of human papillomavirus DNA in breast cancer as revealed by polymerase chain reaction. Breast Cancer Res Treat 39: 197-202.
32. Graflund M, Sorbe B, Sigurdardóttir S, Karlsson M. (2004). HPV-DNA, vascular space invasion, and their impact on the clinical outcome in early-stage cervical carcinomas. Int J Gynecol Cancer 14: 896-902.
33. Grm HS, Massimi P, Gammoh N, Banks L. (2005). Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein. Oncogene 24: 5149-64.
34. Gumus M, Yumuk PF, Salepci T, et al. (2006). HPV DNA frequency and subset analysis in human breast cancer patients’ normal and tumoral tissue samples. J Exp Clin Cancer Res 25: 515-21.
35. Guy CT, Webster MA, Schaller M, et al. (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89: 10578-82.
36. Hachana M, Ziadi S, Amara K, et al. (2010). No evidence of human papillomavirus DNA in breast carcinoma in Tunisian patients. Breast 19: 541-4.
37. Halbert CL, Demers GW, Galloway DA. (1991). The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 65: 473-8.
38. Hedau S, Kumar U, Hussain S, et al. (2011). Breast cancer and human papillomavirus infection: No evidence of HPV etiology of breast cancer in Indian women. BMC Cancer 11: 27.
39. Heng B, Glenn WK, Ye Y, et al. (2009). Human papillomavirus is associated with breast cancer. Br J Cancer 101: 1345-50.
40. Hennig EM, Suo Z, Thoresen S, et al. (1999). Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III). Breast Cancer Res Treat 53: 121-35.
41. Herber R, Liem A, Pitot H, Lambert PF. (1996). Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 70: 1873-81.
42. Kan CY, Iacopetta BJ, Lawson JS, Whitaker NJ. (2005). Identification of human papillomavirus DNA gene sequences in human breast cancer. Br J Cancer 93: 946-8.
43. Khan NA, Castillo A, Koriyama C, et al. (2008). Human papillomavirus detected in female breast carcinomas in Japan. Br J Cancer 99: 408-14.
44. Kim SH, Juhnn YS, Kang S, et al. (2006). Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell Mol Life Sci 63: 930-8.
45. Kroupis C, Markou A, Vourlidis N, et al. (2006). Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. Clin Biochem 39: 727-31.
46. Li N, Bi X, Zhang Y, et al. (2011). Human papillomavirus infection and sporadic breast carcinoma risk: A meta-analysis. Breast Cancer Res Treat 126: 515-20.
47. Liao S, Deng D, Hu X, et al. (2013). HPV16/18E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7. Int J Mol Med 31: 120-8.
48. Lin CQ, Singh J, Murata K, et al. (2000). A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 60: 1332-40.
49. Lindel K, Forster A, Altermatt HJ, et al. (2007). Breast cancer and human papillomavirus (HPV) infection: No evidence of a viral etiology in a group of Swiss women. Breast 16: 172-7.
50. Liu Y, Klimberg VS, Andrews NR, et al. (2001). Human papillomavirus DNA is present in a subset of unselected breast cancers. J Hum Virol 4: 329-34.
51. Longworth MS, Laimins LA. (2004a). Pathogenes is of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68(2): 362-72.
52. Longworth MS, Laimins LA. (2004b). The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 78: 3533-41.
53. Lyden D, Young AZ, Zagzag D, et al. (1999). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401: 670-7.
54. Magal SS, Jackman A, Ish-Shalom S, et al. (2005). Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J Gen Virol 86: 611-21.
55. Maufort JP, Shai A, Pitot HC, Lambert PF. (2010). A role for HPV 16 E5 in cervical carcinogenesis. Cancer Res 70: 2924-31.
56. Maufort JP, Williams SM, Pitot HC, Lambert PF. (2007). Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis. Cancer Res 67: 6106-12.
57. Minn AJ, Gupta GP, Siegel PM, et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436: 518-24.
58. Moody CA, Laimins LA. (2009). Human papillomaviruses activate the ATMDNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog 5: e1000605.
59. Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T. (2004). The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci 50: 9-19.
60. Münger K, Basile JR, Duensing S, et al. (2001). Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20: 7888-98.
61. Nguyen ML, Nguyen MM, Lee D, et al. (2003a). The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6‘s induction of epithelial hyperplasia in vivo. J Virol 77: 6957-64.
62. Nguyen MM, Nguyen ML, Caruana G, et al. (2003b). Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol Cell Biol 23: 8970-81.
63. Noya F, Chien WM, Broker TR, Chow LT. (2001). p21cip1 degradation in differentiated keratinocytes is abrogated by costabilization with cyclin E induced by human papillomavirus E7. J Virol 75: 6121-34.
64. Oh JM, Kim SH, Cho EA, et al. (2010). Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells. Carcinogenesis 31: 402-10.
65. Ong K, Koay ES, Putti TC. (2009). Detection of cutaneous HPV types 4 and 24 DNA sequences in breast carcinoma in Singaporean women of Asian ancestry. Pathology 41: 436-42.
66. Paavonen J, Naud P, Salmerón J, et al. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374: 301-14.
67. Pedroza-Saavedra A, Lam EW, Esquivel-Guadarrama F, Gutierrez-Xicotencatl L. (2010). The human papillomavirus type 16 E5 oncoprotein synergizes with EGF-receptor signaling to enhance cell cycle progression and the down-regulation of p27(Kip1). Virology 400: 44-52.
68. Pereira Suarez AL, Lorenzetti MA, Gonzalez Lucano R, et al. (2013). Presence of human papilloma virus in a series of breast carcinoma from Argentina. PLoS One 8: e61613.
69. Ragin CC, Taioli E. (2007). Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. Int J Cancer 121: 1813-20.
70. Revzina NV, Diclemente RJ. (2005). Prevalence and incidence of human papillomavirus infection in women in the USA: A systematic review. Int J STD AIDS 16: 528-37.
71. Riley RR, Duensing S, Brake T, et al. (2003). Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 63: 4862-71.
72. Rylander E, Ruusuvaara L, Almströmer MW, et al. (1994). The absence of vaginal human papillomavirus 16 DNA in women who have not experienced sexual intercourse. Obstet Gynecol 83: 735-7.
73. Sawaya GF, Smith-McCune K. (2007). HPV vaccination-more answers, more questions. N Engl J Med 356: 1991-3.
74. Shai A, Pitot HC, Lambert PF. (2008). p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 68: 2622-31.
75. Sherman ME, Schiffman MH, Lorincz AT, et al. (2007). Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. Cancer 81: 89-97.
76. Sigaroodi A, Nadji SA, Naghshvar F, et al. (2012). Human papillomavirus is associated with breast cancer in the north part of Iran. ScientificWorldJournal 2012: 837191.
77. Simões PW, Medeiros LR, Simões Pires PD, et al. (2012). Prevalence of human papillomavirus in breast cancer: A systematic review. Int J Gynecol Cancer 22: 343-7.
78. Singh J, Murata K, Itahana Y, Desprez PY. (2002). Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Oncogene 21: 1812-22.
79. Smith JS, Lindsay L, Hoots B, et al. (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 121: 621-32.
80. Song S, Liem A, Miller JA, Lambert PF. (2000). Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 267: 141-50.
81. Song S, Pitot HC, Lambert PF. (1999). The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 73: 5887-93.
82. Stacey SN, Jordan D, Williamson AJ, et al. (2000). Leaky scanning is the predominant mechanism for translation of human papillomavirus type 16 E7 oncoprotein from E6/E7 bicistronic mRNA. J Virol 74: 7284-97.
83. Suprynowicz FA, Disbrow GL, Krawczyk E, et al. (2008). HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells. Oncogene 27: 1071-8.
84. Thomas M, Banks L. (1998). Inhibition of bak-induced apoptosis by HPV-18 E6. Oncogene 17: 2943-54.
85. Thomas M, Laura R, Hepner K, et al. (2002). Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene 21: 5088-96.
86. Tungteakkhun SS, Filippova M, Neidigh JW, et al. (2008). The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. J Virol 82: 9600-14.
87. Umudum H, Rezanko T, Dag F, Dogruluk T. (2005). Human papillomavirus genome detection by in situ hybridization in fine-needle aspirates of metastatic lesions from head and neck squamous cell carcinomas. Cancer 105: 71-7.
88. Varnai AD, Bollmann M, Griefingholt H. (2006). HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN). Impact of HPV analysis of anal lesions on diagnosis and prognosis. Int J Colorectal Dis 21: 135-42.
89. Venuti A, Badaracco G, Rizzo C, et al. (2004). Presence of HPV in head and neck tumours: High prevalence in tonsillar localization. J Exp Clin Cancer Res 23: 561-6.
90. Weigelt B, Peterse JL, van’t Veer LJ. (2005). Breast cancer metastasis: Markers and models. Nat Rev Cancer 5: 591-602.
91. Woods Ignatoski KM, Dziubinski ML, Ammerman C, Ethier SP. (2005). Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells. Neoplasia 7: 788-98.
92. Wrede D, Luqmani YA, Coombes RC, et al. (1992). Absence of HPV 16 and 18 DNA in breast cancer. Br J Cancer 65: 891-4.
93. Yasmeen A, Bismar TA, Dekhil H, et al. (2007c). ErbB-2 receptor cooperates with E6/E7 oncoproteins of HPV type 16 in breast tumorigenesis. Cell Cycle 6: 2939-43.
94. Yasmeen A, Bismar TA, Kandouz M, et al. (2007b). E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle 6: 2038-42.
95. Yasmeen A, Hosein AN, Yu Q, Al Moustafa AE. (2007a). Critical role for D-type cyclins in cellular transformation induced by E6/E7 of human papillomavirus type 16 and E6/E7/ErbB-2 cooperation. Cancer Sci 98: 973-7.
96. Yu Y, Morimoto T, Sasa M, et al. (1999). HPV33 DNA in premalignant and malignant breast lesions in Chinese and Japanese populations. Anticancer Res 19: 5057-61.
97. Yu Y, Morimoto T, Sasa M, et al. (2000). Human papillomavirus type 33 DNA in breast cancer in Chinese. Breast Cancer 7: 33-6.
98. Yuan CH, Filippova M, Duerksen-Hughes P. (2012). Modulation of apoptotic pathways by human papillomaviruses (HPV): Mechanisms and implications for therapy. Viruses 4: 3831-50.
99. Zuna RE, Allen RA, Moore WE, et al. (2004). Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: Evidence for differences in biologic potential of precursor lesions. Mod Pathol 17: 1314-22.